The genomic landscape of breast cancer brain metastases: a systematic review

The genomic landscape of breast cancer brain metastases: a systematic review.
Abstract - Published in Lancet Oncol - January 2021.

"The two most commonly reported genes in both extracranial studies and in this Review were TP53 and PIK3CA".

"Because TP53 mutations were reported in 85 (52%) and PIK3CA mutations were reported in 36 (22%) of the 164 breast cancer brain metastases, these two genes represent the most obvious targets for intervention. PI3Kalpha-specific inhibitor alpelisib has shown activity in PIK3CA-mutated breast cancer.41 The brain penetrant inhibitor paxalisib (GDC-0084) has shown activity in preclinical models of breast cancer brain metastasis 42 and preliminary clinical activity in glioblastoma,43 and there are several ongoing clinical trials in patients with breast cancer and brain metastases"

https://www.researchgate.net/profile/Athina_Giannoudis/publication/348033458_The_genomic_landscape_of_breast_cancer_brain_metastases_a_systematic_review/links/5fed5a50a6fdccdcb81afeaf/The-genomic-landscape-of-breast-cancer-brain-metastases-a-systematic-review.pdf

Will the breast cancer and brain metastases trials for paxalisib, show good efficacy results?

Regards.